Tumor necrosis factor-a receptor (TNFRI)-associated periodic syndrome (TRAPS) is the most common autosomal-dominant autoinflammatory condition and is caused by mutations in the TNFRSFIA gene. TRAPS is characterized by recurrent attacks of fever typically lasting from 1 to 3 weeks; in addition to fever, common clinical features include mainly periorbital oedema, conjunctivitis, a migratory erythematous plaque simulating erysipela with underlying myalgia, and arthritis or arthralgia; serosal membrane inflammation is also possible. The identification of TNFRSFIA mutations as the genetic cause of TRAPS coincided with the wider use of biological agents in medicine and raised the possibility that blocking TNF could potentially represent the primary therapeutic goal in TRAPS, thus disclosing new treatment choices for this complex disease. In the past few years, isolated reports and case-series have been published suggesting that inhibition of TNF-a might represent a promising therapeutic approach in TRAPS. We present here our experience with etanercept in the treatment of patients affected with TRAPS, and we also add a review of the literature. Autoinflammatory disorders are defined by spontaneously relapsing and remitting bouts of systemic inflammation in the absence of pathogens, autoantibodies, or antigen-specific T cells. These disorders can be monogenic or multifactorial and are associated with mutations of genes involved in inflammation and apoptosis (I).
Among monogenic autoinflammatory diseases, the tumor necrosis factor-receptor l-associated periodic syndrome (TRAPS; OM1M 142680) is the most common autosomal dominant autoinflammatory disorder and is characterized by recurrent attacks offever typically lasting from 1 to 3 weeks; in addition to fever, common clinical features include mainly periorbital oedema, conjunctivitis, a migratory erythematous plaque simulating erysipela with underlying myalgia, and arthritis or arthralgia; serosal membrane inflammation is also possible (2) (3) . TRAPS is caused by mutations in the gene TNFRSFIA, located on chromosome l2p13, encoding the 55-kD receptor for' tumor necrosis factor-a (TNF-a) (TNFRSFIA) (4). TNFRSF IA is a transmembrane glycoprotein ( Fig. I ) which consists of an extracellular region characterized by a distinct pattern of 4 cysteine-rich domains (CRDs 1-4), a transmembrane region, and an intracellular death domain (DD), which promotes TNFRSF IA signaling (5) . The binding site for TNFa is formed by CRD2 and CRD3 (6), while CRDI is the pre-ligand assembly binding domain and is thought to mediate TNFRSF IA self-assembly (7) . More than 40 individual mutations have been identified, the majority of which are localised in the CRDI and CRD2 domains (http://fmf.igh.cnrs.fr/infevers/) (8). Most mutations described involve cysteine residues and are associated with a higher disease penetrance, however several variants involving other residues have been reported (9) . In vitro studies suggest that these TRAPS-associated TNFRSF1A mutations are responsible for altered TNFRSFIA expression, impaired TNF-a binding and shedding (4), defective trafficking (10-11) and abnormal apoptosis (3, 12) .
Infliximab

Etanercept Adalimumab
Typical of TRAPS is a wide variability amongst patients both in terms of age of disease onset and frequency, and length and severity of inflammatory attacks. This heterogeneity is related to the complex phenotypical expression of TRAPS and to the wide spectrum of TNFRSF1A mutations (13) .
Patients usually tend to develop a chronic disease course with recurrent flares' of multi-organ manifestations, with or without fever, as well as persistently elevated acute-phase reactants, including serum amyloid-A (SAA) circulating levels, Creactive protein (CRP), erythrocyte sedimentation rate (ESR) and interleukin-6 (IL-6), and IL-8 (14) .
Renal AA amyloidosis is the most serious longterm complication of TRAPS, with a prevalence ranging from 14% to 25%, mainly affecting, but not male; *patient n.6 did not carry mutations, but showed a defective TNFRSF1A shedding (ref4)
., "i limited to, patients who carry mutations involving cysteine residues; patients carrying low penetrance mutations may also develop reactive amyloidosis, although they are usually characterized by a milder disease, if they present a persistent acute phase response (15) (16) .
Treatment strategies
Treatment of TRAPS proves more challenging than other auto inflammatory syndromes due to the wide genetic heterogeneity and to the protean clinical phenotype: some patients experience significant disability over time or develop signs of renal amyloidosis, requiring novel treatment strategies with the aim of better long-term disease control. There are patients who gain some symptomatic relief from high-dose non-steroidal anti-inflammatory drugs, whilst colchicine or immunomodulators such as methotrexate, cyclosporin and thalidomide produce little benefit. Inflammatory attacks usually respond to corticosteroid administration (17) , but often require increasing doses, especially in patients with frequent relapses or continuous symptoms, who become prone to metasteroidal co-morbidities (18) .
The identification of TNFRSF1A mutations as the genetic cause of TRAPS coincided with the wider use of biological agents in medicine, thus disclosing new treatment choices for this complex disease. The fact of the defect in TNFRSF 1A shedding and subsequent inappropriate TNF inhibition suggested that blocking TNF -even though TNF is not increased in most patients (14) -could potentially represent the primary therapeutic goal in TRAPS (19) . Anti-TNF therapy in TRAPS has been based on etanercept, a recombinant human TNFR (p75)-Fc fusion protein comprising two receptors linked by an IgG I Fe fragment. The exact therapeutic profile and dosing regime of etanercept in the long-term management of TRAPS, however, has yet to be established.
The efficacy of etanercept has been shown in single patients and/or in case-series of patients of different ages with fully penetrant TRAPS phenotypes, as evidenced by decreased frequency of attacks and/or decreased severity of disease (20) (21) . Even unusual manifestations such as non-suppurative panniculitis and small-vessel vasculitis were controlled by etanercept in 2 adult patients (22) . In a recently reported case series of 7 patients affected with TRAPS who were treated with etanercept for 24 weeks, although the drug did not completely eliminate inflammatory attacks, it was able to reduce disease activity, also in terms of acute-phase response, and allowed for reduction of corticosteroid dose administration in all cases (23) . Amyloidosis in TRAPS usually presents with nephrotic syndrome, and early treatment of renal involvement with corticosteroids, colchicine or chlorambucil usually fails to prevent end-stage renal failure. Anecdotal reports of successful treatment with etanercept of patients with TRAPS characterized by nephrotic syndrome have recently been described (24) . In addition, etanercept slowed the progression of renal failure due to renal amyloidosis in an 18-year-old patient who underwent renal transplantation at the age of 14 (25) .
In contrast, the administration of other anti-TNF agents, such as infliximab, a mouse-human chimeric monoclonal IgG 1 antibody to TNF, or adalimumab, a fully humanised anti-TNF monoclonal antibody, 'hlay lead to enhanced anti-apoptotic activity, oversecretion of pro-inflammatory cytokines (IL-l, IL-l R, IL-6, IL-8, and IL-12) (11) and paradoxical exacerbation of the TRAPS clinical picture (12, 23, 26) . Differences in response to treatment with different TNF-inhibitors seem to be related to the more stable binding complexes with soluble TNF and to their much higher binding avidity to transmembrane TNF of monoclonal antibodies than etanercept (27) . Moreover, it has been hypothesized that mutations altering the extracellular conformation of TNFR fail to shed infliximab-bound TNF/TNFR from the cell surface, thus leading to the induction of inflammatory responses (12) .
A decrease in responsiveness to etanercept over time has been described in few patients; the authors hypothesized that etanercept efficacy in TRAPS might be non-specific and may reflect 'generic' antiinflammatory properties of the molecule (28) (29) .
There are promising results deriving from the use of anakinra, a recombinant interleukin-I receptor antagonist, in etanercept-resistant patients; in these patients, anakinra prevented disease relapses in the short-term, raising the hypothesis that the dysregulation of IL-l secretion might represent the final common pathway ofdifferent autoinflammatory diseases (30) (31) . To date, the initial results obtained in patients with TRAPS through IL-l inhibition, though promising, are restricted to very few cases and must be subjected to further evaluation in larger cohorts of patients.
Personal experience
To date, of the patients affected with TRAPS whom we are treating with etanercept, 7 have reached a 12-month follow-up. Six patients out of 7 are adults (32) (33) , and 1 is of pediatric age (34) . Of the 6 adults, 4 were characterized by adult disease-onset, whereas 2 reported the onset of symptoms during childhood. Table I summarizes the main characteristics of our cohort of patients. Four patients out of 7 presented recurrent pericarditis as the sole clinical manifestation (32) , and of these, 3 carried the low-penetrance R92Q mutation in TNFRSF1A. In addition, one of these patients presenting with recurrent pericarditis as the sole clinical manifestation carried a novel heterozygous YI03-R104 deletion in the exon 4, characterized by a six-nucleotide heterozygous deletion (TACCGG nucleotide sequence) and causing the loss of the aminoacid tyrosine and arginine at position 103 and 104, respectively (32) . The functional implication of this deletion is currently under investigation in our laboratories. One patient out of the 5 carrying the R92Q mutation was characterized by an unusual association of sacroileitis and pericarditis, in the absence of the most typical clinical signs of TRAPS (33) . The R92Q mutation is common in patients of Mediterranean origin, and in a recent study its frequency in healthy Italian individuals was 2.25%. Moreover, in most of the R92Q patients, the mutation was inherited from one healthy parent (3). Nevertheless, its increased frequency among patients with periodic fever suggests that it is a low-penetrance mutation rather than a benign polymorphism (9) .
Although soluble TNFRSFIA serum levels do not seem to increase with attacks, monocytes from patients bearing the R92Q substitution show TNFRSF 1A membrane staining and receptor shedding comparable to controls, suggesting that additional pathogenetic mechanisms may be operative in TRAPS (9) . Recently, Lobito et al reported that the R92Q variant TNFRSFIA behaves like wild-type TNFRSFIA, with apparently normal folding, identical surface expression and TNF binding (10) . The authors suggested that the pathogenesis of TRAPS in patients harboring only the R92Q variant is probably different from that of patients carrying other mutations. The R92Q allele may therefore cause milder disease, and may often be associated with an oligosymptomatic course (16, 35) .
The low-penetrance TNFRSFIA variant seems to contribute to atypical inflammatory responses in TRAPS, including cardiac diseases (myocarditis and pericarditis) (17, (32) (33) 36) . In addition, we recently further confirmed the potential role of mutations in the TNFRSF1A gene in patients with recurrent idiopathic pericarditis (37) .
The pediatric patient, on the other hand, presented with a severe clinical picture, although she carried a low-penetrance D12E mutation characterized by a T to G transition in exon 2 which substitutes an aspartic acid for a glutamic acid at position 12 (Dl2E; c.123T>G). The D12E mutation was initially supposed to determine a milder disease and also a shorter duration of fever attacks (3). The same mutation was subsequently described by Gattorno et al. in a patient who was also carrying a homozygous M680I mutation on the MEFV gene, responsible for familial Mediterranean fever (FMF); that patient was classified as having FMF (31) .
Although missense substitutions of cysteine or threonine residues are associated with a more aggressive disease course (10), patients with severe TRAPS caused by a non-cysteine mutation (T50M) in the TNFRSFIA gene have been reported (2, 9, 25) . The functional implication of the Dl2E mutation is also currently under investigation in our laboratories.
All 7 of our patients had previously been treated with prednisone, and they required chronic administration ofhigh doses in order to prevent flares and achieve good disease control. In addition, SAA circulating levels increased even during symptomfree intervals. For these reasons, treatment with etanercept was started.
Etanercept determined the resolution of fever and of other disease-related clinical manifestations and allowed the reduction of corticosteroid administration, up to suspension in all cases. At l-year follow-up, none of the patients showed any sign of disease relapse and, in addition, SAA levels checked at least three times were persistently within normal range. Apart from skin reactions at the site of the injections, which were observed in 2 out of 7 patients, no serious adverse events were observed.
CONCLUSIONS
To date, etanercept has been shown to be efficacious in treating TRAPS in most cases; its administration may prevent disease flares and/or permit reduction of corticosteroid administration. Anecdotal reports also describe its efficacy in the treatment of TRAPS-related reactive amyloidosis. Nevertheless, a decline in responsiveness may occur in some cases. Among the TNF-n neutralizing agents, infliximab and adalimumab may cause paradoxical inflammatory attacks, and caution is strongly advised when prescribing them to patients with TRAPS. In etanercept-resistant patients, IL-l inhibition proved successful. Though promising, the results obtained with IL-l antagonists are, to date, limited to very few cases and must undergo further evaluation in larger cohorts of patients. Our data, although obtained with patients carrying low-penetrance mutations (5/7) and presenting incomplete disease (4/7), confirm etanercept as a possible first-line treatment option in the treatment of TRAPS. Nonetheless, the definite role of etanercept in the management of TRAPS and its long-term benefit and potential adverse effects will be further assessed in large-scale trials.
